Agilent Technologies, Inc.

Read together, the scores describe a company whose reported figures pass the main screens, while the narrative leans on growth and savings that a careful reader should test. The Beneish M-Score is -2.464, which is below the -1.78 threshold and so sits outside the elevated manipulation-risk zone. This is a screening output, not proof that the figures are accurate; it only means the model did not flag them. The Altman Z-Score is 6.09, which falls in the safe zone and suggests low near-term distress risk on the 2025 balance sheet. The Piotroski F-Score is 6 of 8 computable signals, meaning six of the standard checks on profitability, leverage and operating efficiency that could be computed were passed; the data does not show which two were not computable. The Fog Index of 22.21 is in the very hard to read band, so the MD&A's discussion of restructuring, hedging and critical estimates takes more effort to follow than a typical filing. Segment detail in the 10-Q shows Life Sciences and Diagnostics Markets up 9% for the nine months, Agilent CrossLab up 7%, and Applied Markets up 9%. Fiscal 2025 revenue growth of 6.7% and operating cash flow to net income of 1.20 are consistent with reported profit, but operating income edged down to $1.48 billion from $1.49 billion. Readers may want to look at the full Item 1A risk factors, because the excerpt provided is mostly a table of contents and does not show the company's own list of risks, and at the Agilent Advanced Therapeutics disclosures, which the MD&A cites as a leading growth driver.

Catalyst.Management's MD&A, covering the nine months ended July 31, 2026, reports total net revenue of $5.51 billion, up 8% from $5.09 billion a year earlier. Growth was led by product revenue, specifically Agilent Advanced Therapeutics (formerly the specialty CDMO business), consumables, and liquid chromatography mass spectrometry. Currency added a 2 percentage point favorable impact over the nine months, so part of the reported growth did not come from underlying demand. The Life Sciences and Diagnostics Markets segment rose 9% for the nine months, with pharmaceutical and diagnostics strength partly offset by declines in academia and government. Restructuring expense for the nine months was $43 million, down from $74 million a year earlier, and management expects the FY26 plan to reduce annual costs by $30 million to $35 million.

Hidden risk.Two restructuring plans in consecutive fiscal years suggest cost reductions are recurring rather than one-time, even though the filing frames them as management optimization. The FY25 plan has carried $109 million of expense since inception and the FY26 plan $15 million. Long-term debt rose from $1.79 billion in 2019 to $3.35 billion in 2024 before falling to $3.05 billion in 2025, against total liabilities of $5.99 billion and assets of $12.73 billion. Operating cash flow fell from $1.75 billion in 2024 to $1.56 billion in 2025 while net income rose to $1.3 billion. Cash flow still exceeded net income at 1.20 times, but the gap narrowed. The MD&A also names goodwill and purchased intangible asset valuation as a critical accounting estimate, and its Fog Index of 22.21 places it in the very hard to read band, which makes those estimates harder to check.